Efficacy and Safety of Hizentra(®), a New 20% Immunoglobulin Preparation for Subcutaneous Administration, in Pediatric Patients with Primary Immunodeficiency

Subcutaneous IgG treatment for primary immunodeficiencies (PI) is particularly well suited for children because it does not require venous access and is mostly free of systemic adverse events (AEs). In a prospective, open-label, multicenter, single-arm, Phase III study, 18 children and five adolesce...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Borte, Michael, Pac, Malgorzata, Serban, Margit, Gonzalez-Quevedo, Teresa, Grimbacher, Bodo, Jolles, Stephen, Zenker, Othmar, Neufang-Hueber, Jutta, Belohradsky, Bernd
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Springer US 2011
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3221851/
https://ncbi.nlm.nih.gov/pubmed/21674136
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10875-011-9557-z
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak